Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK's RSV Vaccine (Arexvy) in Japanese Adults 60-80 Years
NCT04090658Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Solicited Local Adverse Events After First Dose of Vaccination at 7 days, Number of Subjects With Solicited Local Adverse Events After Second Dose of Vaccination at 7 days and 7 more. Started Sep 2019; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04090658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04090658.